PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases

Amyloid-β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project

(2019) Sander C. J. Verfaillie et al.   Frontiers in Aging Neuroscience

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences

(2019) Arno de Wilde et al.   Alzheimers Research & Therapy

Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years

(2018) Suzanne E. Schindler et al.   Alzheimers & Dementia

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease

(2018) Niklas Mattsson et al.   Alzheimers & Dementia

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

(2018) Oskar Hansson et al.   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Amsterdam Dementia Cohort: Performing Research to Optimize Care

(2018) Wiesje M. van der Flier et al.   JOURNAL OF ALZHEIMERS DISEASE

Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort

(2018) Arno de Wilde et al.   JAMA Neurology

Longitudinal Changes of CSF Biomarkers in Alzheimer's Disease

(2018) Toni T. Seppälä et al.   JOURNAL OF ALZHEIMERS DISEASE

Optimizing Patient Care and Research: The Amsterdam Dementia Cohort

(2018) Wiesje M. van der Flier et al.   JOURNAL OF ALZHEIMERS DISEASE

MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study

(2018) Mara ten Kate et al.   Alzheimers Research & Therapy

The Cerebrospinal Fluid Aβ1–42/Aβ1–40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer’s Disease in a Clinical Setting

(2017) Ellis Niemantsverdriet et al.   JOURNAL OF ALZHEIMERS DISEASE

Structural variation in amyloid-β fibrils from Alzheimer's disease clinical subtypes

(2017) Wei Qiang et al.   NATURE

Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease

(2017) Colin Groot et al.   NEUROLOGY

Diagnostic impact of [18F]flutemetamol PET in early-onset dementia

(2017) Marissa D. Zwan et al.   Alzheimers Research & Therapy

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

(2016) Sebastian Palmqvist et al.   BRAIN

Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer’s Disease

(2016) Piotr Lewczuk et al.   JOURNAL OF ALZHEIMERS DISEASE

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

(2015) Osama Sabri et al.   Alzheimers & Dementia

What does it mean to be ‘amyloid-positive’?

(2015) Anne M. Fagan   BRAIN

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

(2015) Willemijn J. Jansen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Amyloid biomarkers in Alzheimer's disease

(2015) Kaj Blennow et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density

(2015) Craig Curtis et al.   JAMA Neurology

mice: Multivariate Imputation by Chained Equations inR

(2015) Stef van Buuren et al.   Journal of Statistical Software

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

(2014) Frank Jessen et al.   Alzheimers & Dementia

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease

(2014) Niklas Mattsson et al.   BRAIN

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics

(2014) Kristin R Wildsmith et al.   Molecular Neurodegeneration

Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions

(2014) R. Ossenkoppele et al.   NEUROLOGY

Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice

(2014) Stephanie J. B. Vos et al.   PLoS One

Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease

(2014) A. M. Fagan et al.   Science Translational Medicine

Longitudinal Amyloid Imaging Using 11C-PiB: Methodologic Considerations

(2013) B. N. M. van Berckel et al.   JOURNAL OF NUCLEAR MEDICINE

Biomarker Modeling of Alzheimer’s Disease

(2013) Clifford R. Jack et al.   NEURON

Impact of molecular imaging on the diagnostic process in a memory clinic

(2012) Rik Ossenkoppele et al.   Alzheimers & Dementia

Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET

(2012) Rik Ossenkoppele et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

(2012) Christopher M Clark et al.   LANCET NEUROLOGY

Indicators of amyloid burden in a population-based study of cognitively normal elderly

(2012) M. M. Mielke et al.   NEUROLOGY

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Visual assessment of posterior atrophy development of a MRI rating scale

(2011) Esther L. G. E. Koedam et al.   EUROPEAN RADIOLOGY

Classification of primary progressive aphasia and its variants

(2011) M. L. Gorno-Tempini et al.   NEUROLOGY

Absence of Pittsburgh Compound B Detection of Cerebral Amyloid β in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease

(2009) Nigel J. Cairns et al.   ARCHIVES OF NEUROLOGY

Cerebrospinal fluid tau and ptau181increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease

(2009) Anne M. Fagan et al.   EMBO Molecular Medicine

Fibrillar amyloid-  burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease

(2009) E. M. Reiman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Conditional Variable Importance for Random Forests

(2008) Carolin Strobl et al.   BMC BIOINFORMATICS

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

(2008) Milos D. Ikonomovic et al.   BRAIN

Second consensus statement on the diagnosis of multiple system atrophy

(2008) S. Gilman et al.   NEUROLOGY